by Market Overview:
Gallbladder cancer is a rare type of cancer that forms in the gallbladder, a small organ located under the liver that stores and releases bile. Gallbladder cancer usually does not cause any signs or symptoms in its early stages. As it grows, common symptoms may include pain or discomfort in the upper abdominal area, weight loss, swelling or lump in the upper abdominal area, jaundice and loss of appetite. Surgical resection is typically the primary treatment for gallbladder cancer. Radiation therapy and chemotherapy may also be used before or after surgery.
Market Dynamics:
Rising incidence of gallbladder cancer is expected to drive the market growth over the forecast period. According to CDC, approximately 12,000 new cases of gallbladder cancer were reported in the U.S. in 2021.Moreover, increasing investment in R&D of novel targeted therapies such as Lenvatinib, Pembrolizumab, and Larotrectinib etc. for gallbladder cancer treatment is also assisting the market growth. For instance, in 2022, Eisai announced the FDA approval expansion of Lenvima (lenvatinib) plus pembrolizumab for the treatment of advanced endometrial carcinoma in the U.S. Lenvima in combination with pembrolizumab is already approved for certain types of advanced liver cancer worldwide. Furthermore, increasing healthcare expenditures along with growing awareness about early cancer diagnosis is fueling the market growth.
The global Gallbladder Cancer Market Demand is estimated to be valued at US$ 73.6 Mn or Million in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The gallbladder cancer market can be segmented into carcinoma, sarcoma and others by type. Among them, carcinoma dominates the market as it accounts for over 90% of all gallbladder cancer cases. This is because carcinoma arises from the epithelial cells that line the gallbladder, making it the most common type.
PEST Analysis
Political: Regulations supporting cancer screening and subsidizing treatment costs in certain countries can drive the market growth. However, lack of awareness in low-income nations hampers it.
Economic: Rising healthcare spending on oncology in emerging economies and growing R&D investments by key players to develop new drugs are fueling the market.
Social: Increasing risk of gallbladder cancer due to sedentary lifestyle, obesity and metabolic disorders in developed regions is boosting the demand.
Technological: Advancements in cancer diagnostics, targeted therapies and immunotherapy have improved outcomes. Collaborations for combination therapies hold promise.
Key Takeaways
The global gallbladder cancer market is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing cases and improved diagnosis.
The market size for 2023 is US$ 73.6 million. Higher healthcare spending and availability of advanced treatments are supporting the market growth in North America, making it the dominant regional market.
Asia Pacific is anticipated to be the fastest growing market, expanding at a CAGR of around 6%, due to large patient population, rising standards of living, and improving access to healthcare in developing countries.
Key players operating in the gallbladder cancer market are Eli Lilly and Company, Bristol-Myers Squibb, Roche, Pfizer, Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, AbbVie, Gilead Sciences. Major players are focusing on R&D and partnerships to develop novel therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
